On Tuesday, Nurix Therapeutics Inc (NASDAQ: NRIX) opened lower -2.79% from the last session, before settling in for the closing price of $21.49. Price fluctuations for NRIX have ranged from $6.58 to $29.56 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 38.34% over the past five years. Company’s average yearly earnings per share was noted -6.20% at the time writing. With a float of $68.89 million, this company’s outstanding shares have now reached $70.84 million.
Let’s look at the performance matrix of the company that is accounted for 284 employees. In terms of profitability, gross margin is 71.85%, operating margin of -343.3%, and the pretax margin is -313.19%.
Nurix Therapeutics Inc (NRIX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nurix Therapeutics Inc is 2.74%, while institutional ownership is 95.15%. The most recent insider transaction that took place on Dec 02 ’24, was worth 125,155. In this transaction Chief Legal Officer of this company sold 5,760 shares at a rate of $21.73, taking the stock ownership to the 28,084 shares. Before that another transaction happened on Dec 02 ’24, when Company’s Officer proposed sale 5,760 for $22.11, making the entire transaction worth $127,354.
Nurix Therapeutics Inc (NRIX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -6.20% per share during the next fiscal year.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Check out the current performance indicators for Nurix Therapeutics Inc (NRIX). In the past quarter, the stock posted a quick ratio of 5.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.91, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.76 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NASDAQ: NRIX) saw its 5-day average volume 0.65 million, a negative change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 32.01%. Additionally, its Average True Range was 1.41.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 27.35%, which indicates a significant increase from 5.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.02% in the past 14 days, which was higher than the 55.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.97, while its 200-day Moving Average is $19.39. Nevertheless, the first resistance level for the watch stands at $21.47 in the near term. At $22.06, the stock is likely to face the second major resistance level. The third major resistance level sits at $22.54. If the price goes on to break the first support level at $20.40, it is likely to go to the next support level at $19.92. Assuming the price breaks the second support level, the third support level stands at $19.33.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
There are currently 70,836K shares outstanding in the company with a market cap of 1.48 billion. Presently, the company’s annual sales total 76,990 K according to its annual income of -143,950 K. Last quarter, the company’s sales amounted to 12,590 K and its income totaled -48,960 K.
